Aetiologies of Hyperprolactinaemia

Objectives This study aimed to evaluate the aetiologies of hyperprolactinaemia in the United Arab Emirates (UAE). Methods This retrospective study used laboratory databases to identify all patients who underwent evaluation for prolactin at Tawam Hospital, Al Ain, UAE, between 2009 and 2015. Of those 2,280 patients, all patients with low or normal prolactin (n = 1,315) were excluded. Subsequently, charts of the remaining patients (n = 965) with hyperprolactinaemia were reviewed and those with incomplete work-ups or insufficient documentation of the hyperprolactinaemia’s aetiology were excluded (n = 458). Results A total of 507 patients were included in the study. The average age at prolactin evaluation was 36 ± 13.2 years and the majority (67.1%) of patients were female. The most common reasons for requesting prolactin were menstrual disorders (29.5%), infertility (18%), evaluation of sellar masses (14.3%), ruling out seizures (13.4 %) and monitoring while on psychiatric medications (8.7%). The most common causes of hyperprolactinaemia were prolactinoma (17%), transient hyperprolactinaemia (14.6%), drug-induced side effects (14.4%), polycystic ovarian syndrome (11.8%) and seizure disorder (7.7%). In females, common aetiologies were prolactinomas, transient and idiopathic hyperprolactinaemia, while sellar masses, seizures, chronic kidney disease and acute illnesses were common aetiologies of hyperprolactinaemia in males. The prolactin level varied between the different aetiologies and a level of >250 ng/mL was suggestive of macro-prolactinoma. Conclusion A significant proportion of patients with hyperprolactinaemia have transient hyperprolactinaemia. Before further investigations are carried out, prolactin level assessment should be repeated, especially in patients with mild hyperprolactinaemia.

[1]  H. Randeva,et al.  The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome , 2018, European journal of clinical investigation.

[2]  M. AlMalki,et al.  Clinical and epidemiological characteristics of pituitary tumours in a single centre in Saudi Arabia , 2018, Hormones.

[3]  J. Abucham,et al.  Controversial issues in the management of hyperprolactinemia and prolactinomas – An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism , 2018, Archives of endocrinology and metabolism.

[4]  F. Alosaimi,et al.  Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications , 2018, International journal of psychiatry in clinical practice.

[5]  J. Kulkarni,et al.  Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research , 2017, Psychopharmacology.

[6]  G. Leese,et al.  The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS) , 2017, Clinical endocrinology.

[7]  I. Wambacq,et al.  Diagnostic value of serum prolactin levels in PNES in the epilepsy monitoring unit , 2016, Neurology. Clinical practice.

[8]  S. Doucette,et al.  Sellar Masses: An Epidemiological Study , 2015, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[9]  P. Chanson,et al.  New insights in prolactin: pathological implications , 2015, Nature Reviews Endocrinology.

[10]  S. Aylwin,et al.  Importance of cannulated prolactin test in the definition of hyperprolactinaemia , 2015, Pituitary.

[11]  M. Fleseriu,et al.  Challenges and pitfalls in the diagnosis of hyperprolactinemia. , 2014, Arquivos brasileiros de endocrinologia e metabologia.

[12]  M. Rattanachaiyanont,et al.  Hyperprolactinemia: a 12-year retrospective study at gynecologic endocrinology unit, Siriraj Hospital. , 2013, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[13]  Marta García,et al.  Physiological and Pathological Hyperprolactinemia: Can We Minimize Errors in the Clinical Practice? , 2013 .

[14]  A. Shimatsu,et al.  Macroprolactinemia: Diagnostic, Clinical, and Pathogenic Significance , 2012, Clinical & developmental immunology.

[15]  Victor M Montori,et al.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[16]  W. Tormey,et al.  The Beckman DxI 800 prolactin assay demonstrates superior specificity for monomeric prolactin , 2010, Clinical chemistry and laboratory medicine.

[17]  M. Gadelha,et al.  Diagnosis and management of hyperprolactinemia: Results of a Brazilian multicenter study with 1234 patients , 2008, Journal of endocrinological investigation.

[18]  R. Fisher,et al.  Use of serum prolactin in diagnosing epileptic seizures , 2005, Neurology.

[19]  S. Masoodi,et al.  Clinical and etiological profile of hyperprolactinemia--data from a tertiary care centre. , 2005, The Journal of the Association of Physicians of India.

[20]  S. Ezzat,et al.  Diagnosis and management of hyperprolactinemia. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[21]  B. Wannamaker,et al.  Serum prolactin and cortisol levels in evaluation of pseudoepileptic seizures , 1985, Annals of neurology.

[22]  J. Schenker,et al.  Transient hyperprolactinemia: a correctable cause of idiopathic female infertility. , 1983, The Journal of clinical endocrinology and metabolism.